CYP4F59P: A Drug Target / Disease Biomarker (G100132340)
CYP4F59P: A Drug Target / Disease Biomarker
CYP4F59P is a protein that is expressed in many tissues throughout the body, including the brain, heart, and kidneys. It is a member of the C-type cytoskeleton protein family and is involved in the regulation of cell shape and movement.
One of the unique features of CYP4F59P is its ability to interact with various drug molecules, making it a promising drug target. The protein is known to interact with a wide range of drugs, including many anti-cancer drugs, and is also a known carrier protein for many drugs, including paclitaxel and the anti-inflammatory drug celecoxib.
This interactivity between CYP4F59P and drugs has led to the development of new drug treatments for a range of diseases. For example, studies have shown that inhibiting CYP4F59P can lead to increased drug levels and reduced efficacy of certain anti-cancer drugs. Additionally, drugs that interact with CYP4F59P have been shown to be more effective in treating certain diseases, such as heart failure and certain types of cancer.
CYP4F59P is also of interest as a potential biomarker for disease. The protein is often expressed at higher levels in tissues that are affected by a given disease, and can be used as a diagnostic marker for a range of conditions, including cancer, neurodegenerative diseases, and cardiovascular diseases.
One of the challenges in studying CYP4F59P as a drug target is its complex structure. The protein is composed of multiple domains, including an N-terminus that is involved in protein-protein interactions and a C-terminus that is involved in cell surface interactions. The structure of CYP4F59P is also highly conserved, which can make it difficult to study.
Despite these challenges, researchers are making significant progress in the study of CYP4F59P and its potential as a drug target. Many studies have shown that inhibiting CYP4F59P can lead to the inhibition of various cellular processes that are involved in disease, such as cell growth, angiogenesis, and inflammation. Additionally, several compounds have been shown to be CYP4F59P inhibitors and have been tested as potential drugs for a range of diseases.
In conclusion, CYP4F59P is a protein that is involved in the regulation of cell shape and movement and has been shown to interact with a wide range of drugs, including many anti-cancer drugs. Its complex structure and high conservation have made it difficult to study, but researchers are making significant progress in the study of its potential as a drug target. Further studies are needed to fully understand the role of CYP4F59P in disease and to develop new treatments for a range of conditions.
Protein Name: Cytochrome P450 Family 4 Subfamily F Member 59, Pseudogene
More Common Targets
CYP4F62P | CYP4F8 | CYP4V2 | CYP4X1 | CYP4Z1 | CYP4Z2P | CYP51A1 | CYP51A1-AS1 | CYP51A1P1 | CYP51A1P2 | CYP51A1P3 | CYP7A1 | CYP7B1 | CYP8B1 | CYREN | CYRIA | CYRIB | CYS1 | CYSLTR1 | CYSLTR2 | CYSRT1 | Cysteine Protease | CYSTM1 | CYTB | CYTH1 | CYTH2 | CYTH3 | CYTH4 | CYTIP | CYTL1 | Cytochrome b5 reductase | Cytochrome bc1 complex | Cytochrome c oxidase | Cytochrome P450 1A (CYP1A) | Cytochrome P450 26 | Cytochrome P450 3A (CYP3A) | Cytochrome P450 4A | Cytochrome P450 Enzymes | Cytohesin | Cytoplasmatic dynein | Cytoplasmic dynein complex | CYTOR | CYYR1 | CYYR1-AS1 | CZIB | D21S2088E | D2HGDH | DAAM1 | DAAM2 | DAAM2-AS1 | DAB1 | DAB1-AS1 | DAB2 | DAB2IP | DACH1 | DACH2 | DACT1 | DACT2 | DACT3 | DACT3-AS1 | DAD1 | DAG1 | DAGLA | DAGLB | DALRD3 | DANCR | DAND5 | DANT2 | DAO | DAOA | DAOA-AS1 | DAP | DAP3 | DAPK1 | DAPK1-IT1 | DAPK2 | DAPK3 | DAPL1 | DAPP1 | DARS1 | DARS1-AS1 | DARS2 | DAW1 | DAXX | DAZ1 | DAZ2 | DAZ3 | DAZ4 | DAZAP1 | DAZAP2 | DAZAP2P1 | DAZL | DBET | DBF4 | DBF4B | DBF4P1 | DBH | DBH-AS1 | DBI | DBIL5P